DGAP-News: Neovacs S.A. / Key word(s): Conference
NEOVACS TO PRESENT AT BIO EUROPE SPRING 2015
19.02.2015 / 08:00
---------------------------------------------------------------------
PRESS RELEASE
NEOVACS TO PRESENT AT BIO EUROPE SPRING 2015
Paris, February 19, 2015 - NEOVACS (Alternext Paris: ALNEV), a leader in
active immunotherapies for the treatment of autoimmune diseases, announced
today that the Company will be presenting at the BIO Europe Spring 2015
Partnering Conference to be held in Paris, Porte de Versailles, on March
9-11, 2015.
The spring edition of BIO Europe Conference attracts thousands of
representatives from the biotechnology and pharmaceutical industries.
Miguel Sieler, CEO of Neovacs, will present on March 10, 2015 at 4:30 pm
C.E.T. Neovacs will be attending the three-day conference with a booth.
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused
on an active immunotherapy technology platform (Kinoids) with applications
in autoimmune and/or inflammatory diseases. On the basis of the company's
proprietary technology for inducing a polyclonal immune response (covered
by five patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy
being developed for the indication of lupus. Neovacs is also conducting
preclinical development works on other therapeutic vaccines in the fields
of auto-immune diseases, oncology and allergies. The goal of the Kinoid
approach is to enable patients to have access to safe treatments with
efficacy that is sustained in these life-long diseases.
For more information on Neovacs, visit www.neovacs.fr
Contacts
NEOVACS
Nathalie Trépo
+33 (0)1 53 10 93 00
ntrepo@neovacs.com
Press - Financial Communications- Publicis
Stéphanie Tabouis
+33 (0) 1 44 82 46 35
stéphanie.tabouis@consultants.publicis.fr
Investor Relations - Financial Communications Germany - MC Services
Raimund Gabriel
+49-89-210228-30
Raimund.Gabriel@mc-services.eu
Press - U.S. Inquiries - The Ruth Group
Melanie Sollid-Penton
1.646.536.7023
msollid@theruthgroup.com
---------------------------------------------------------------------
19.02.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Neovacs S.A.
3-5, Impasse Reille
75014 Paris
France
Phone: +33 (0)1 53 10 93 00
Fax: +33 (0)1 53 10 93 03
E-mail: www.neovacs.fr
Internet: info@neovacs.fr
ISIN: FR0004032746
WKN: A1CVKR
Listed: Regulated Unofficial Market in Stuttgart; Open Market in
Frankfurt
End of News DGAP News-Service
---------------------------------------------------------------------
324837 19.02.2015
DGAP-News: NEOVACS TO PRESENT AT BIO EUROPE SPRING 2015
| Source: EQS Group AG